SCHEMBL8301499

SCHEMBL8301499

COc1ccc(C(=O)C(=O)Nc2cccnc2)c2c1oc1ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.46
RAB9A P51151 6/20 0.46
MAPT P10636 5/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
KDM4E B2RXH2 4/20 0.46
TSHR P16473 1/20 0.46
GAA P10253 1/20 0.46
AHR P35869 1/20 0.46
LMNA P02545 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
PDE4B Q07343 2/20 0.45
POLB P06746 2/20 0.44
NOTUM Q6P988 1/20 0.44
PKM P14618 1/20 0.43
PDE4A P27815 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
TP53 P04637 3/20 0.42
HSD17B10 Q99714 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5018075 0.90 NPC1 (0.55) NPC1RAB9AMAPTSMN1; SMN2KDM4E
SCHEMBL8302112 0.89 NPC1 (0.46) NPC1RAB9AMAPTSMN1; SMN2TSHR
SCHEMBL8301459 0.89 PDE4B (0.53) NPC1RAB9AMAPTSMN1; SMN2KDM4E
SCHEMBL8300121 0.87 PDE4B (0.47) NPC1RAB9AMAPTSMN1; SMN2KDM4E
SCHEMBL8298185 0.85 PDE4A (0.46) NPC1RAB9AMAPTSMN1; SMN2KDM4E
SCHEMBL8298189 0.82 PDE4B (0.62) PDE4BPDE4APDE4CPDE4D
SCHEMBL5018001 0.80 LRRK2 (0.51) NPC1RAB9AMAPTSMN1; SMN2KDM4E
SCHEMBL5023240 0.78 PDE4B (0.63) NPC1RAB9AMAPTSMN1; SMN2LMNA
SCHEMBL3995780 0.78 KMT2A (0.46) MAPTSMN1; SMN2KDM4ETSHRGAA
SCHEMBL4034779 0.78 GAA (0.53) NPC1RAB9AMAPTSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004111044-A1 TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS:PROCESS FOR THEIR PREPARATION GLENMARK PHARMACEUTICALS LTD. (US) 2004-12-23 WO disclosed